← Back to Search

STING Agonist

E7766 for Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Eisai Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose of study drug until confirmed cr or pr or >=5 weeks after first dose for sd (up to 29 months)
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and works against advanced solid tumors or lymphomas.

Eligible Conditions
  • Lymphoma
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose of study drug until confirmed icr or ipr or >=5 weeks after first dose for isd (up to 29 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose of study drug until confirmed icr or ipr or >=5 weeks after first dose for isd (up to 29 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Escalation Part: Number of Participants With Dose-limiting Toxicities (DLTs)
Dose Expansion Part: DCR Based on iRECIST
Dose Expansion Part: DOR Based on iRECIST
+5 more
Secondary outcome measures
AUC(0-inf): Area Under the Plasma Concentration From Time Zero to Infinity Curve for E7766
Cmax: Maximum Observed Plasma Concentration for E7766
Dose Escalation Part: CL/F: Apparent Total Body Clearance for E7766
+19 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose Expansion: Advanced Solid Tumors or LymphomasExperimental Treatment1 Intervention
Dose identified from dose escalation part for E7766 will be used in dose expansion part.
Group II: Dose Escalation: Advanced Solid Tumors or LymphomasExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Eisai Inc.Lead Sponsor
515 Previous Clinical Trials
153,996 Total Patients Enrolled
17 Trials studying Lymphoma
969 Patients Enrolled for Lymphoma
H3 Biomedicine Inc.Industry Sponsor
6 Previous Clinical Trials
509 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
2020. "Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04144140.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top